Eicke Latz Selected Research

Inflammasomes

1/2022	NLRP6 Inflammasome Modulates Disease Progression in a Chronic-Plus-Binge Mouse Model of Alcoholic Liver Disease.
11/2021	BTK operates a phospho-tyrosine switch to regulate NLRP3 inflammasome activity.
7/2021	Topical inflammasome inhibition with disulfiram prevents irritant contact dermatitis.
1/2021	The Specific NLRP3 Antagonist IFM-514 Decreases Fibrosis and Inflammation in Experimental Murine Non-Alcoholic Steatohepatitis.
1/2021	Bidirectional Role of NLRP3 During Acute and Chronic Cholestatic Liver Injury.
1/2021	Inflammasome-induced extracellular vesicles harbour distinct RNA signatures and alter bystander macrophage responses.
12/2020	Platelets Fuel the Inflammasome Activation of Innate Immune Cells.
10/2020	Cholesterol crystals use complement to increase NLRP3 signaling pathways in coronary and carotid atherosclerosis.
2/2020	Author Correction: AIM2 inflammasome-derived IL-1β induces postoperative ileus in mice.
1/2020	Enduring Changes in Neuronal Function upon Systemic Inflammation Are NLRP3 Inflammasome Dependent.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Eicke Latz Research Topics

Disease

63	Inflammation (Inflammations) 02/2022 - 08/2006
24	Infections 01/2022 - 12/2008
18	Atherosclerosis 01/2022 - 04/2010
11	Autoimmune Diseases (Autoimmune Disease) 01/2022 - 02/2005
9	Alzheimer Disease (Alzheimer's Disease) 01/2020 - 08/2008
8	Neurodegenerative Diseases (Neurodegenerative Disease) 10/2021 - 01/2013
7	Fibrosis (Cirrhosis) 02/2022 - 11/2015
7	Atherosclerotic Plaque (Atheroma) 01/2022 - 03/2013
6	Pneumonia (Pneumonitis) 02/2022 - 01/2010
6	Disease Progression 01/2022 - 01/2010
6	Neoplasms (Cancer) 01/2022 - 01/2017
5	Bites and Stings (Sting) 01/2021 - 11/2010
5	Type 2 Diabetes Mellitus (MODY) 01/2021 - 05/2011
5	Neuroinflammatory Diseases 01/2021 - 01/2013
5	Rupture 01/2019 - 01/2013
4	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2018 - 02/2005
4	Obesity 10/2017 - 05/2011
4	Metabolic Diseases (Metabolic Disease) 09/2015 - 08/2011
4	Virus Diseases (Viral Diseases) 01/2014 - 05/2003
3	Silicosis 02/2022 - 08/2008
3	Cognitive Dysfunction 01/2022 - 01/2013
3	COVID-19 01/2022 - 01/2020
3	Hypertension (High Blood Pressure) 11/2021 - 01/2017
3	Cardiovascular Diseases (Cardiovascular Disease) 09/2021 - 03/2013
3	Melanoma (Melanoma, Malignant) 01/2019 - 03/2009
3	Fever (Fevers) 03/2010 - 09/2003
2	Lung Injury 02/2022 - 01/2021
2	Dementia (Dementias) 01/2022 - 01/2019
2	Parkinson Disease (Parkinson's Disease) 10/2021 - 01/2020
2	Contact Dermatitis (Eczema, Contact) 07/2021 - 01/2018
2	Hereditary Sensory and Autonomic Neuropathies (HSAN) 01/2021 - 01/2017
2	Non-alcoholic Fatty Liver Disease 01/2021 - 09/2015
2	Hyperglycemia 01/2021 - 05/2011
2	Dysbiosis 01/2021 - 12/2015
2	Tauopathies 01/2021 - 11/2019
2	Acute Lung Injury 01/2021 - 02/2015
2	Ileus 02/2020 - 01/2019
2	Cryopyrin-Associated Periodic Syndromes 10/2017 - 03/2015
2	Multiple Sclerosis 01/2016 - 03/2015
2	Colitis 12/2015 - 09/2010
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 11/2015 - 09/2015
2	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 03/2015 - 02/2008
2	Malaria 01/2014 - 02/2007
2	Lung Diseases (Lung Disease) 01/2014 - 08/2008

Drug/Important Bio-Agent (IBA)

61	InflammasomesIBA 01/2022 - 08/2008
24	CytokinesIBA 01/2021 - 04/2003
22	Proteins (Proteins, Gene)FDA Link 01/2022 - 02/2005
17	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 02/2005
14	CholesterolIBA 01/2021 - 04/2010
9	Amyloid (Amyloid Fibrils)IBA 01/2020 - 01/2013
8	Interleukin-18 (Interleukin 18)IBA 02/2022 - 04/2010
7	RNA (Ribonucleic Acid)IBA 01/2021 - 10/2006
6	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2016 - 12/2005
5	Interleukin-1 (Interleukin 1)IBA 01/2022 - 04/2010
5	Complement System Proteins (Complement)IBA 01/2022 - 03/2014
5	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2018
5	N- (1,2,3,5,6,7- hexahydro- S- indacen- 4- ylcarbamoyl)- 4- (2- hydroxy- 2- propanyl)- 2- furansulfonamideIBA 01/2021 - 03/2015
5	InterleukinsIBA 10/2020 - 04/2010
5	Peptides (Polypeptides)IBA 01/2018 - 08/2008
4	LipidsIBA 12/2021 - 03/2013
4	NLR ProteinsIBA 01/2021 - 08/2011
4	InterferonsIBA 01/2021 - 04/2012
4	Toll-Like Receptor 9IBA 04/2010 - 02/2005
3	Silicon Dioxide (Silica)FDA LinkGeneric 02/2022 - 08/2008
3	Pharmaceutical PreparationsIBA 01/2022 - 09/2003
3	Apolipoproteins E (ApoE)IBA 01/2022 - 01/2016
3	SaltsIBA 11/2021 - 01/2017
3	LigandsIBA 02/2021 - 08/2013
3	ChemokinesIBA 01/2021 - 02/2005
3	Interferon Type IIBA 01/2021 - 01/2016
3	NucleotidesIBA 01/2021 - 11/2015
3	Pyrin Domain-Containing 3 Protein NLR FamilyIBA 10/2020 - 02/2015
3	Biological ProductsIBA 01/2020 - 02/2007
3	Amyloid beta-PeptidesIBA 11/2019 - 08/2008
3	Nucleotide AptamersIBA 01/2019 - 01/2018
3	Antiviral Agents (Antivirals)IBA 11/2017 - 04/2012
3	AutoantibodiesIBA 12/2012 - 02/2005
2	Tetracycline (Achromycin)FDA LinkGeneric 02/2022 - 01/2021
2	AntibodiesIBA 01/2022 - 04/2012
2	VaccinesIBA 01/2022 - 04/2016
2	Desoxycorticosterone (Deoxycorticosterone)IBA 11/2021 - 01/2017
2	Irritants (Vesicants)IBA 07/2021 - 01/2010
2	PyrinIBA 01/2021 - 03/2009
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2021 - 11/2015
2	DNA receptor (receptor, DNA)IBA 01/2021 - 04/2012
2	SphingolipidsIBA 01/2021 - 01/2017
2	Leucine (L-Leucine)FDA Link 01/2021 - 01/2018
2	Desoxycorticosterone Acetate (DOCA)FDA Link 01/2019 - 01/2017
2	CollagenIBA 01/2019 - 01/2017
2	Liposomes (Liposome)IBA 01/2019 - 01/2018
2	Bacterial DNAIBA 01/2019 - 03/2011
2	Pathogen-Associated Molecular Pattern MoleculesIBA 01/2018 - 10/2016
2	OligodeoxyribonucleotidesIBA 01/2018 - 04/2010
2	Pattern Recognition ReceptorsIBA 01/2018 - 04/2015
2	CyclodextrinsIBA 10/2017 - 04/2016
2	Nucleic AcidsIBA 11/2016 - 01/2016
2	OxysterolsIBA 04/2016 - 09/2015
2	hemozoinIBA 01/2014 - 02/2007

Therapy/Procedure

14	Therapeutics 01/2022 - 04/2003
2	Immunotherapy 11/2019 - 06/2018